KENSEY NASH ANGIO-SEAL AND DATASCOPE VASOSEAL ARE APPROVABLE, FDA ADVISORY PANEL CONCLUDES; WARNINGS ABOUT HIGH RISK GROUPS MUST BE IN LABELING
This article was originally published in The Gray Sheet
Kensey Nash's Angio-Seal and Datascope's VasoSeal hemostasis devices should have warnings in labeling about the lack of clinical data supporting their safety and efficacy in high risk patients, FDA's Circulatory Systems Devices Panel recommended at its May 8 meeting in Gaithersburg, Maryland.
You may also be interested in...
FDA Commissioner Stephen Hahn was added to the White House's pandemic task force as the outbreak grew, but he remained in a background role. That all changed the morning of 18 March, when President Trump tweeted: “I will be having a news conference today to discuss very important news from the FDA concerning the Chinese Virus!” A day later, Hahn was standing with Trump at the podium for the now-daily press briefings on Covid-19.
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.